/KRON
KRON Stock - Kronos Bio, Inc.
Healthcare|BiotechnologyNASDAQ
$0.88+1.49%
+$0.01 (+1.49%) • Jun 20
72
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.63
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.54
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+515.9%upside
Target: $5.42
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KRON
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.87 – $0.89
TARGET (TP)$5.42
STOP LOSS$0.81
RISK/REWARD1:64.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.64
52W High$1.46
52W Low$0.65
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.85M | $6.29M | N/A | N/A | N/A |
| Gross Profit | $9.85M | $6.29M | $-4,463,000 | $-4,081,000 | $-4,866,000 |
| Gross Margin | 100.0% | 100.0% | N/A | N/A | N/A |
| Operating Income | $-92,887,000 | $-121,830,000 | $-137,115,000 | $-151,398,000 | $-58,044,000 |
| Net Income | $-86,079,000 | $-112,673,000 | $-129,293,000 | $-149,101,000 | $-64,087,000 |
| Net Margin | -874.1% | -1791.9% | N/A | N/A | N/A |
| EPS | $-1.43 | $-1.95 | $-2.30 | $-2.72 | $-1.19 |
Company Overview
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
33%
Hold / Neutral
2
67%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
1 Bullish2 Neutral/Bearish
Price Targets
$7
Average Target
↑ 638.6% Upside
Now
$1
Low
$7
Average
$12
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 14th 2024 | Piper Sandler | Downgrade | Neutral | $1← $6 |
| November 14th 2024 | TD Cowen | Downgrade | Hold | - |
| September 14th 2022 | Berenberg | Initiation | Buy | $12 |
Earnings History & Surprises
KRONBeat Rate
42%
Last 19 quarters
Avg Surprise
-2.7%
EPS vs Estimate
Beats / Misses
8/10
1 met exactly
Latest EPS
$-0.14
Q2 2025
EPS Surprise History
Q3 23
-4.0%
$-0.52vs$-0.50
Q4 23
-5.9%
$-0.54vs$-0.51
Q1 24
+15.7%
$-0.43vs$-0.51
Q2 24
-16.3%
$-0.50vs$-0.43
Q3 24
+15.6%
$-0.27vs$-0.32
Q4 24
+11.5%
$-0.23vs$-0.26
Q1 25
-43.3%
$-0.43vs$-0.30
Q2 25
+53.3%
$-0.14vs$-0.30
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | May 8, 2025 | $-0.30 | $-0.14 | +53.3% | ✓ BEAT |
Q1 2025 | Mar 18, 2025 | $-0.30 | $-0.43 | -43.3% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.26 | $-0.23 | +11.5% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.32 | $-0.27 | +15.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.43 | $-0.50 | -16.3% | ✗ MISS |
Q1 2024 | Mar 21, 2024 | $-0.51 | $-0.43 | +15.7% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.51 | $-0.54 | -5.9% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-0.50 | $-0.52 | -4.0% | ✗ MISS |
Q2 2023 | May 10, 2023 | $-0.43 | $-0.46 | -7.0% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $-0.55 | $-0.56 | -1.8% | ✗ MISS |
Q4 2022 | Nov 8, 2022 | $-0.64 | $-0.57 | +10.9% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.69 | $-0.59 | +14.5% | ✓ BEAT |
Q2 2022 | May 4, 2022 | $-0.65 | $-0.65 | 0.0% | = MET |
Q1 2022 | Feb 24, 2022 | $-1.07 | $-1.13 | -5.6% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.98 | $-0.61 | +37.8% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.51 | $-0.53 | -3.9% | ✗ MISS |
Q2 2021 | May 11, 2021 | $-0.43 | $-0.48 | -11.6% | ✗ MISS |
Q1 2021 | Mar 23, 2021 | $-1.10 | $-0.44 | +60.0% | ✓ BEAT |
Q4 2020 | Nov 18, 2020 | $-1.47 | $-4.00 | -172.1% | ✗ MISS |
Q4 2020 | Oct 9, 2020 | — | $-0.17 | — | — |
Latest News
Loading news...
Frequently Asked Questions about KRON
What is KRON's current stock price?
Kronos Bio, Inc. (KRON) is currently trading at $0.88 per share. The stock has moved +1.49% today.
What is the analyst price target for KRON?
The average analyst price target for KRON is $5.42, based on 1 analyst.
What sector is Kronos Bio, Inc. in?
Kronos Bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KRON's market cap?
Kronos Bio, Inc. has a market capitalization of $0.05 billion, making it a small-cap company.
Does KRON pay dividends?
No, Kronos Bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHL
Achilles Therapeutics plc
$1.48
Mkt Cap: $0.1B
ALVR
AlloVir, Inc.
$9.81
Mkt Cap: $0.0B
ARPO
Aerpio Pharmaceuticals, Inc.
$2.20
Mkt Cap: $0.1B
BLUE
bluebird bio, Inc.
$4.97
Mkt Cap: $0.0B
RENB
Lunai Bioworks Inc.
$1.42
Mkt Cap: $0.0B
RNTX
Rein Therapeutics Inc.
$1.42
Mkt Cap: $0.0B
RPHM
Reneo Pharmaceuticals, Inc.
$18.20
Mkt Cap: $0.1B
SGTX
Sigilon Therapeutics, Inc.
$22.47
Mkt Cap: $0.1B
SYRE
Spyre Therapeutics, Inc.
$33.40
Mkt Cap: $2.0B
TCRR
TCR2 Therapeutics Inc.
$1.48
Mkt Cap: $0.1B
Explore stocks similar to KRON for comparison